InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.20
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,641.86
(
0.55%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 18

Saturday, 02/24/2018 6:04:13 PM

Saturday, February 24, 2018 6:04:13 PM

Post# of 438
CATB

Ph2 results for DMD treatment on 2/14/18 were impressive.

Ph3 will begin H-2 2018. It will read out 2020.

The compound is a sythentic combination of DHA and aspirin. (Dr.
Jack Kruse may be right about DHA)

This compound should be worth a minimum of 300mn, yet the MC of CATB is ~40mn

Sarepta's approved treatment is only indicated in 14% of DMD patients.

Cash = 21.7mn on 9/30/17.

When/if financing issues are resolved, this will probably be a buy.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up